Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* males, 18 or older~* proven advanced prostate cancer~* documented metastatic disease~* rising PSA levels~* castrate levels of testosterone~Exclusion Criteria:~* symptomatic CNS (brain or spinal cord) metastasis~* medical condition which may increase the risk of toxicity~* any prior or ongoing anti-cancer medical therapy or immunotherapy for prostate cancer other than primary androgen deprivation agents~* unable to take oral medication

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).